PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.43%
Cash & equivalents declining -3.43% while TRVN's grows 2.41%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.43%
Below half of TRVN's 2.41%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
967.92%
Above 1.5x TRVN's 63.79%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-3.05%
Below half of TRVN's 7.16%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
0.98%
Below half TRVN's -3.64%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x TRVN's -13.56%. Michael Burry warns of potential hidden liabilities or intangible bloat.
0.98%
Below half of TRVN's -21.74%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Below half of TRVN's 1.48%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-106.99%
Exceeding 1.5x TRVN's -3.02%. Michael Burry suspects ballooning short-term obligations vs. competitor.
16.37%
Above 1.5x TRVN's 1.96%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of TRVN's 3.89%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.58%
Similar yoy to TRVN's 3.34%. Walter Schloss sees parallel expansions in total liabilities.
3.85%
Less than half of TRVN's 55.56%. David Dodd sees fewer share issuances vs. competitor.
-5.06%
≥ 1.5x TRVN's -1.44%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.22%
≥ 1.5x TRVN's -3.66%. David Dodd sees stronger capital base growth than competitor.
-2.92%
Below half TRVN's 1.48%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.00%
Less than half of TRVN's 2.45%. David Dodd sees less overall debt expansion vs. competitor.
3.39%
Less than half of TRVN's -2.31%. David Dodd sees better deleveraging or stronger cash buildup than competitor.